Compounded Semaglutide: Legal Status, Risks, and What Changed

The Rise and Regulation of Compounded Semaglutide

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for diabetes management and weight loss, became the subject of intense regulatory scrutiny between 2022 and 2024. During a critical window when shortages of FDA-approved formulations created access barriers, compounded versions flourished in the market. Understanding what happened, why, and what it means for current patients requires examining both regulatory authority and clinical evidence.

Semaglutide was first approved by the FDA in 2008 under the brand name Victoza for type 2 diabetes, followed by approval for chronic weight management as Wegovy in 2021. The approved formulations—manufactured by Novo Nordisk—are subject to rigorous manufacturing standards, stability testing, and quality control required of FDA-approved drugs. These medications are Schedule III controlled substances due to their potential for abuse, though this classification applies only to approved versions and carries specific handling requirements.

When supply shortages of Wegovy emerged in 2021-2023, driven by extraordinary demand following viral social media attention and off-label prescribing trends, a regulatory gap opened. Compounding pharmacies—facilities operating under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act—began producing semaglutide solutions using pharmaceutical-grade raw materials. These compounded versions were never approved by the FDA, but federal law permits pharmacies to compound medications under specific circumstances, particularly when an FDA-approved version is unavailable or when a patient requires a different dosage form than what's commercially available.

The Shortage Window: Why Compounding Filled a Gap

Compounding pharmacies operate under two primary regulatory pathways. Section 503A covers traditional compounding by state-licensed pharmacies for individual patients based on valid prescriptions, which generally receives limited federal oversight as long as pharmacies follow state regulations and the ingredients used are legitimate pharmaceutical-grade materials. Section 503B covers outsourcing facilities, which are federally registered and inspected, permitted to compound drugs without individual patient prescriptions for general distribution.

Many semaglutide compounds were prepared under 503A frameworks, with prescribers citing patient access and shortage justification. The appeal was obvious: compounded semaglutide was significantly cheaper than branded Wegovy, often costing one-third to one-half the price. For uninsured patients or those without coverage for weight-loss medications, this price differential was transformative. However, the lack of FDA oversight meant no requirement for stability data, sterility testing, or assurance of consistent dosing across batches. Additionally, many compounding pharmacies did not hold DEA registration for handling Schedule III controlled substances, raising legal questions about whether compounded semaglutide should have been treated as a controlled substance at all.

The Salt Form Controversy: A Critical Scientific Issue

The most substantive scientific controversy surrounding compounded semaglutide centered on salt form. Novo Nordisk's Victoza and Wegovy contain semaglutide as a salt—specifically, semaglutide acetate. This choice was deliberate: salt forms often improve stability, solubility, and bioavailability compared to free-base versions. The FDA approval process validated this particular formulation through human clinical trials demonstrating safety and efficacy with the acetate salt.

Many compounding pharmacies used semaglutide as the free base rather than the acetate salt, primarily because the free base form was more readily available from raw material suppliers. While both forms contain the same active peptide, the salt form affects physical and chemical properties including solubility, crystal structure, and potentially absorption rates. Limited evidence exists directly comparing free-base semaglutide to the acetate salt form in human studies. Some theoretical concerns include altered bioavailability or stability, though the magnitude of any difference remains unknown. This represents a genuine gap: the free-base compounds were never studied in human clinical trials, meaning their safety and efficacy profiles differ from the FDA-approved standard.

Regulatory Action and Current Status

In 2023-2024, regulatory agencies took increasingly firm positions on compounded semaglutide. The FDA issued statements clarifying that compounded semaglutide was not approved and lacked the quality assurances of FDA-regulated drugs. More significantly, as supply of branded Wegovy and Victoza improved and shortages resolved, the justification for 503A compounding under shortage conditions weakened considerably. By late 2023, many state pharmacy boards began restricting or prohibiting semaglutide compounding, particularly for weight loss indications where FDA alternatives became reliably available.

The DEA also addressed the controlled substance question. Only FDA-approved semaglutide products are designated Schedule III. Compounded versions technically exist in a gray area—they are not Schedule III by explicit listing, but questions remained about whether compounders should treat them as such given their connection to approved controlled substances. This created additional legal exposure for compounders and prescribers.

Currently, most U.S. states have restricted compounded semaglutide availability significantly or entirely. Patients and providers cannot assume they can legally obtain compounded versions; state-by-state variation is substantial, and regulatory conditions continue evolving.

Risks and Clinical Considerations

The primary concern with compounded semaglutide relates to quality assurance. FDA-approved products undergo stability testing across temperature ranges and storage conditions, with ongoing quality monitoring. Compounded products, particularly those using the free-base form or prepared by facilities without FDA inspection, lack this documentation. Patients risk receiving inconsistent doses across refills, potentially affecting therapeutic response or safety.

Sterility and pyrogenicity (contamination with fever-inducing bacterial fragments) represent additional concerns with injectable compounded medications. While legitimate compounding pharmacies follow USP standards for sterile preparation, not all facilities maintain equivalent quality controls.

For patients currently using compounded semaglutide, the evidence base for harm is limited but not absent. Case reports have documented injection site reactions, inconsistent weight loss, and glycemic control issues potentially attributable to product variability, though causation cannot be established from individual cases.

Options for Current Patients

Patients previously using compounded semaglutide who no longer have access face several alternatives. FDA-approved semaglutide products are now consistently available. Insurance coverage varies substantially, but patient assistance programs from Novo Nordisk and other manufacturers can significantly reduce out-of-pocket costs. Generic options may become available following patent expiration. Discussing these alternatives with prescribers remains the most appropriate next step, as clinical judgment about individual risk-benefit profiles cannot be replaced by regulatory guidance alone.